{{Rsnum
|rsid=1523130
|Gene=NR1I2
|Chromosome=3
|position=119780660
|Orientation=minus
|GMAF=0.4761
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NR1I2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 12.5 | 45.5 | 42.0
| HCB | 6.6 | 39.0 | 54.4
| JPT | 8.8 | 37.2 | 54.0
| YRI | 85.0 | 13.6 | 1.4
| ASW | 75.0 | 25.0 | 0.0
| CHB | 6.6 | 39.0 | 54.4
| CHD | 6.4 | 31.2 | 62.4
| GIH | 23.8 | 55.4 | 20.8
| LWK | 84.5 | 15.5 | 0.0
| MEX | 5.2 | 62.1 | 32.8
| MKK | 57.7 | 41.0 | 1.3
| TSI | 18.6 | 43.1 | 38.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=21715435
|Title=Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
}}

{{PMID Auto
|PMID=24232815
|Title=Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy
}}

{{PMID Auto
|PMID=23371894
|Title=Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
}}

{{PMID Auto
|PMID=23492909
|Title=Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers.
}}

{{PMID Auto
|PMID=23609392
|Title=Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}